Andreessen Horowitz is starting to invest in an area of healthcare that the firm has historically avoided
- When Andreessen Horowitz was founded in 2009, the venture capital firm didn’t expect to invest in healthcare.
- That changed in 2015, when the firm launched its $200 million bio-fund, which focused on investing in software companies in healthcare.
- Now on its second bio-fund, the firm has historically avoid investing in therapeutics. That’s beginning to change, general partner Jorge Conde told Business Insider.
- Conde told Business Insider he’s on the hunt for companies using technologies that are “new to the world,” to make better bets on drug development.
Initially, the plan was to steer clear of healthcare.
Andreessen Horowitz, a top Silicon